Network Pharmacology and Molecular Docking Analysis Reveal the Therapeutic Potential of Artemisia annua L. in Systemic Lupus Erythematosus

Artemisia annua L. , a traditional Chinese herb, has been used to manage inflammatory diseases, including systemic lupus erythematosus ( SLE ). However, its active components and molecular mechanisms in treating SLE remain unclear. Active compounds were identified using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform with criteria of drug-likeness ≥0.18 and oral bioavailability ≥30%. SLE-related genes were retrieved from DrugBank, Online Mendelian Inheritance in Man, Therapeutic Target Database, and GeneCards using the search term ‘systemic lupus erythematosus.’ Protein–protein interaction networks were constructed using Search Tool for the Retrieval of Interacting Genes/Proteins, and the Kyoto Encyclopaedia of Genes and Genomes and Gene Ontology enrichment analyses were performed via the DAVID platform. Molecular docking was conducted using AutoDock software. Eight core disease-related genes and five key active compounds were identified through topological analysis. Gene ontology and kyoto encyclopaedia of genes and genomes analyses indicated that the compounds primarily influenced cancer development risk, negative regulation of cell death, and related signalling pathways. Molecular docking confirmed strong binding affinities between key phytochemicals and core SLE targets . The active compounds identified in this study target the following genes: interleukin-6, tumour protein p53, epidermal growth factor receptor, protein kinase B, interleukin-1 beta, tumour necrosis factor, jun proto-oncogene, and B-cell lymphoma 2, which regulate inflammation, T-cell differentiation, and apoptosis. These findings suggest Artemisia annua L. is a source of multitarget therapeutic agents for SLE, warranting further experimental validation. • Artemisia annua L. has a therapeutic effect on systemic lupus erythematosus. • Artemisia annua L. can treat systemic lupus erythematosus by controlling apoptosis. • Works by regulating T-cell differentiation and reducing inflammatory factors. • Investigate the molecular mechanism via network pharmacology and molecular docking.

Authors

Institutions

Publication Details

Journal
Journal of Herbal Medicine
Published
2025-04-09
DOI
https://doi.org/10.1016/j.hermed.2025.101013
Citations
1
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
1.67
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Network Pharmacology and Molecular Docking Analysis Reveal the Therapeutic Potential of Artemisia annua L. in Systemic Lupus Erythematosus

Jiping Xiong, Weiwei Huang
1 citations
Journal of Herbal Medicine
Systemic Lupus Erythematosus Research
1.67
article

Network Pharmacology and Molecular Docking Analysis Reveal the Therapeutic Potential of Artemisia annua L. in Systemic Lupus Erythematosus

Jiping Xiong, Weiwei Huang
article en
1 citations

Abstract

Artemisia annua L. , a traditional Chinese herb, has been used to manage inflammatory diseases, including systemic lupus erythematosus ( SLE ). However, its active components and molecular mechanisms in treating SLE remain unclear. Active compounds were identified using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform with criteria of drug-likeness ≥0.18 and oral bioavailability ≥30%. SLE-related genes were retrieved from DrugBank, Online Mendelian Inheritance in Man, Therapeutic Target Database, and GeneCards using the search term ‘systemic lupus erythematosus.’ Protein–protein interaction networks were constructed using Search Tool for the Retrieval of Interacting Genes/Proteins, and the Kyoto Encyclopaedia of Genes and Genomes and Gene Ontology enrichment analyses were performed via the DAVID platform. Molecular docking was conducted using AutoDock software. Eight core disease-related genes and five key active compounds were identified through topological analysis. Gene ontology and kyoto encyclopaedia of genes and genomes analyses indicated that the compounds primarily influenced cancer development risk, negative regulation of cell death, and related signalling pathways. Molecular docking confirmed strong binding affinities between key phytochemicals and core SLE targets . The active compounds identified in this study target the following genes: interleukin-6, tumour protein p53, epidermal growth factor receptor, protein kinase B, interleukin-1 beta, tumour necrosis factor, jun proto-oncogene, and B-cell lymphoma 2, which regulate inflammation, T-cell differentiation, and apoptosis. These findings suggest Artemisia annua L. is a source of multitarget therapeutic agents for SLE, warranting further experimental validation. • Artemisia annua L. has a therapeutic effect on systemic lupus erythematosus. • Artemisia annua L. can treat systemic lupus erythematosus by controlling apoptosis. • Works by regulating T-cell differentiation and reducing inflammatory factors. • Investigate the molecular mechanism via network pharmacology and molecular docking.

Journal of Herbal MedicineVol. 51
Suizhou Central Hospital (CN), Chengdu University of Traditional Chinese Medicine (CN)
Zero hunger
Openalex Percentile: Top 19%
Systemic Lupus Erythematosus Research
1.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.